Myriad Genetics Announces Executive and Director Changes
Ticker: MYGN · Form: 8-K · Filed: Oct 3, 2025 · CIK: 899923
| Field | Detail |
|---|---|
| Company | Myriad Genetics Inc (MYGN) |
| Form Type | 8-K |
| Filed Date | Oct 3, 2025 |
| Risk Level | medium |
| Pages | 2 |
| Reading Time | 3 min |
| Key Dollar Amounts | $0.01 |
| Sentiment | neutral |
Sentiment: neutral
Topics: management-change, executive-compensation, board-of-directors
Related Tickers: MYGN
TL;DR
MYGN board shakeup and exec comp changes effective Sept 29.
AI Summary
Myriad Genetics, Inc. announced on September 29, 2025, changes in its board and executive team. The filing details the departure of certain officers and directors, the election of new directors, and updates to compensatory arrangements for key executives. These changes are effective as of September 29, 2025.
Why It Matters
Changes in leadership and executive compensation can signal shifts in company strategy or financial health, impacting investor confidence and future performance.
Risk Assessment
Risk Level: medium — Changes in executive and director roles can indicate internal instability or strategic shifts, which may carry inherent risks.
Key Players & Entities
- MYRIAD GENETICS INC (company) — Registrant
- September 29, 2025 (date) — Effective date of changes
- Delaware (jurisdiction) — State of incorporation
- 801-584-3600 (phone_number) — Registrant's telephone number
FAQ
What specific roles have been affected by the departures and appointments?
The filing indicates the departure of certain officers and directors, the election of new directors, and updates to compensatory arrangements for certain officers, but does not specify the exact roles affected in this excerpt.
When were these changes officially reported?
The Form 8-K was filed as of October 3, 2025, reporting events that occurred on September 29, 2025.
What is Myriad Genetics' state of incorporation?
Myriad Genetics, Inc. is incorporated in Delaware.
What is the primary business of Myriad Genetics?
Myriad Genetics, Inc. operates in the 'IN VITRO & IN VIVO DIAGNOSTIC SUBSTANCES' sector, classified under SIC code 2835.
Where is Myriad Genetics' principal executive office located?
The principal executive offices are located at 322 North 2200 West, Salt Lake City, Utah 84116.
Filing Stats: 713 words · 3 min read · ~2 pages · Grade level 11.6 · Accepted 2025-10-03 16:27:00
Key Financial Figures
- $0.01 — ange on which registered Common Stock, $0.01 par value MYGN Nasdaq Global Select Mar
Filing Documents
- mygn-20250929.htm (8-K) — 27KB
- 0000899923-25-000091.txt ( ) — 166KB
- mygn-20250929.xsd (EX-101.SCH) — 2KB
- mygn-20250929_def.xml (EX-101.DEF) — 14KB
- mygn-20250929_lab.xml (EX-101.LAB) — 25KB
- mygn-20250929_pre.xml (EX-101.PRE) — 15KB
- mygn-20250929_htm.xml (XML) — 3KB
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. MYRIAD GENETICS, INC. Date: October 3, 2025 By: /s/ Benjamin R. Wheeler Benjamin R. Wheeler Chief Financial Officer